849807-01-8

Basic information

• Product Name: {4-[(2-fluorophenyl)methoxy]phenyl}methanamine
• Synonyms: {4-[(2-fluorophenyl)methoxy]phenyl}methanamine
• CAS NO: 849807-01-8
• Molecular Formula: C₁₄H₁₄FNO
• Molecular Weight: 231.27
• Mol File: 849807-01-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: {4-[(2-fluorophenyl)methoxy]phenyl}methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: {4-[(2-fluorophenyl)methoxy]phenyl}methanamine(849807-01-8)
• EPA Substance Registry System: {4-[(2-fluorophenyl)methoxy]phenyl}methanamine(849807-01-8)

Safety Data

• Hazardous Substances Data: 849807-01-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-[(2-fluorophenyl)methoxy]phenylmethanamine is used as a chemical intermediate for the development of new pharmaceutical compounds. Its unique molecular structure may contribute to the creation of novel drugs with potential applications in treating various diseases and conditions.
Used in Synthesis of Other Chemical Compounds:
4-[(2-fluorophenyl)methoxy]phenylmethanamine serves as a building block in the synthesis of other complex chemical compounds, which could have a wide range of applications in different industries, including pharmaceuticals, materials science, and chemical manufacturing.
Used in Treatment of Various Diseases and Conditions:
Although further research is needed, 4-[(2-fluorophenyl)methoxy]phenylmethanamine may have potential applications in the treatment of various diseases and conditions due to its unique molecular structure and properties. It could be explored for its potential therapeutic effects in areas such as oncology, neurology, and cardiovascular medicine.

Upstream product

• 852690-97-2 4-[(2-fluorophenyl)methoxy]benzonitrile 
• 767-00-0 4-cyanophenol 
• 446-48-0 o-fluorobenzyl bromide 

Downstream Products

• 1262534-85-9 (R)-N-4'-((2''-fluoro)benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-hydroxypropionamide 

Relevant articles and documents

Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient α-helical N-terminal ‘‘lid’’ segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds.

PAIN TREATING COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.

Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity

Several antiepileptic drugs exert their activities by inhibiting Na + currents. Recent studies demonstrated that compounds containing a biaryl-linked motif (Ar-X-Ar′) modulate Na+ currents. We, and others, have reported that compound

Merging the structural motifs of functionalized amino acids and α-Aminoamides: Compounds with Significant Anticonvulsant Activities

Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs) that exhibit pronounced anticonvulsant activities. We combined key structural pharmacophores present in FAAs and AAAs to generate a new series of compounds and document that select compounds exhibit activity superior to either the prototypical FAA (lacosamide) or the prototypical AAA (safinamide) in the maximal electroshock (MES) seizure model in rats. A representative compound, (R)-N-4′-((3′′-fluoro) benzyloxy)benzyl 2-acetamido-3-methoxypropionamide ((R)-10), was tested in the MES (mice, ip), MES (rat, po), psychomotor 6 Hz (32 mA) (mice, ip), and hippocampal kindled (rat, ip) seizure tests providing excellent protection with ED50 values of 13, 14, ～10 mg/kg, and 12 mg/kg, respectively. In the rat sciatic nerve ligation model (ip), (R)-10 (12 mg/kg) provided an 11.2-fold attenuation of mechanical allodynia. In the mouse biphasic formalin pain model (ip), (R)-10 (15 mg/kg) reduced pain responses in the acute and the chronic inflammatory phases.